While Novo Nordisk and Eli Lilly are fierce rivals in the booming obesity treatment market, they agree on one key point: treatment options need to be broadened and tailored to different types of patient.
That is the concept of patient segmentation and the two frontrunners took big steps forward in revealing their strategies in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?